BLUE241018P1000
- 0.50
- -0.10-16.67%
bluebird bio Newsroom
Bluebird Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bluebird Bio Announces Completion of Its Q2 2024 Form 10-Q Filing
bluebird bio | 10-Q: Q2 2024 Earnings Report
Bluebird Bio's Restructuring Efforts and Financial Outlook: A Cautious Hold Rating
Pfizer Withdraws Sickle Cell Drug Oxbryta Over Safety Concerns
Bluebird Bio Is Maintained at Equal-Weight by Wells Fargo
Bluebird Bio Analyst Ratings
Wells Fargo Maintains Bluebird Bio(BLUE.US) With Hold Rating, Cuts Target Price to $2
Express News | Bluebird bio Inc : Wells Fargo Cuts Target Price to $2 From $3
Maintaining Hold on Bluebird Bio: Balancing LYFGENIA's Promise Against Financial and Operational Hurdles
Barclays Maintains Bluebird Bio(BLUE.US) With Buy Rating, Maintains Target Price $4
Analysts Are Bullish on Top Healthcare Stocks: Bluebird Bio (BLUE), Immunic (IMUX)
William Blair Maintains Bluebird Bio(BLUE.US) With Hold Rating
William Blair Reaffirms Their Hold Rating on Bluebird Bio (BLUE)
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
USA gene therapy company bluebird bio (BLUE.US) initiates restructuring plan, plans to lay off 25% of staff.
The usa gene therapy company bluebird bio announced plans to cut about a quarter of its workforce, as this biotechnology company faces the challenging environment that gene therapy companies face.
Bluebird Bio Announces Restructuring and Targets Break-Even
Bluebird Bio to Cut 25% of Workforce in Restructuring
Bluebird Bio to Cut Workforce by About 25%
Express News | Bluebird bio Shares up 2% Premarket, Co to Cut 25% of Workforce as Part of Restructuring